Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urology | 7 | 2019 | 16 | 2.550 |
Why?
|
| Malpractice | 5 | 2015 | 10 | 1.710 |
Why?
|
| Prostatic Neoplasms | 9 | 2019 | 110 | 1.250 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2019 | 180 | 1.040 |
Why?
|
| Kidney Neoplasms | 6 | 2018 | 61 | 1.010 |
Why?
|
| Clinical Competence | 2 | 2015 | 230 | 0.860 |
Why?
|
| Prostate | 6 | 2019 | 32 | 0.780 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2012 | 26 | 0.700 |
Why?
|
| Testicular Neoplasms | 4 | 2010 | 23 | 0.690 |
Why?
|
| Ureteral Neoplasms | 1 | 2019 | 3 | 0.670 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 11 | 0.670 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2018 | 36 | 0.670 |
Why?
|
| SEER Program | 4 | 2013 | 38 | 0.640 |
Why?
|
| Ureteral Calculi | 1 | 2018 | 2 | 0.640 |
Why?
|
| Ureteroscopy | 1 | 2018 | 2 | 0.640 |
Why?
|
| Kidney Calculi | 1 | 2018 | 4 | 0.640 |
Why?
|
| Simulation Training | 2 | 2019 | 34 | 0.610 |
Why?
|
| Lymph Node Excision | 4 | 2008 | 27 | 0.610 |
Why?
|
| Stents | 1 | 2018 | 76 | 0.610 |
Why?
|
| Prostatectomy | 5 | 2012 | 21 | 0.610 |
Why?
|
| Nephrectomy | 4 | 2018 | 29 | 0.600 |
Why?
|
| Models, Educational | 1 | 2017 | 36 | 0.590 |
Why?
|
| Internship and Residency | 2 | 2018 | 213 | 0.580 |
Why?
|
| Penile Neoplasms | 2 | 2008 | 3 | 0.510 |
Why?
|
| Humans | 39 | 2019 | 29829 | 0.480 |
Why?
|
| Male | 30 | 2019 | 15858 | 0.480 |
Why?
|
| Image-Guided Biopsy | 3 | 2019 | 26 | 0.470 |
Why?
|
| Nephrons | 1 | 2012 | 6 | 0.420 |
Why?
|
| Middle Aged | 21 | 2019 | 9953 | 0.410 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 16 | 0.410 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 32 | 0.400 |
Why?
|
| Urologic Diseases | 1 | 2011 | 5 | 0.400 |
Why?
|
| Sarcoidosis | 1 | 2011 | 14 | 0.390 |
Why?
|
| Marital Status | 1 | 2010 | 15 | 0.370 |
Why?
|
| Insurance, Liability | 1 | 2010 | 1 | 0.370 |
Why?
|
| Postoperative Complications | 6 | 2018 | 957 | 0.350 |
Why?
|
| Aged | 17 | 2018 | 9633 | 0.330 |
Why?
|
| Adult | 14 | 2018 | 8731 | 0.290 |
Why?
|
| Retrospective Studies | 8 | 2018 | 3325 | 0.280 |
Why?
|
| Ultrasonography | 2 | 2019 | 224 | 0.280 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2004 | 107 | 0.280 |
Why?
|
| Liability, Legal | 1 | 2006 | 7 | 0.270 |
Why?
|
| Biopsy, Needle | 2 | 2005 | 101 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 1247 | 0.260 |
Why?
|
| Female | 11 | 2019 | 16417 | 0.260 |
Why?
|
| United States | 5 | 2015 | 2344 | 0.250 |
Why?
|
| Pneumothorax | 1 | 2005 | 12 | 0.250 |
Why?
|
| Unnecessary Procedures | 1 | 2005 | 24 | 0.240 |
Why?
|
| Adenocarcinoma | 2 | 2003 | 194 | 0.240 |
Why?
|
| Genes, erbB-2 | 1 | 2004 | 6 | 0.240 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2004 | 12 | 0.230 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 46 | 0.230 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2003 | 7 | 0.220 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 332 | 0.220 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2003 | 1 | 0.220 |
Why?
|
| Urinary Bladder | 2 | 2004 | 20 | 0.220 |
Why?
|
| Collagen | 1 | 2003 | 102 | 0.220 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 12 | 0.220 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 1859 | 0.210 |
Why?
|
| Genital Neoplasms, Male | 1 | 2002 | 3 | 0.210 |
Why?
|
| Seminal Vesicles | 1 | 2002 | 4 | 0.210 |
Why?
|
| Glycoproteins | 1 | 2003 | 57 | 0.210 |
Why?
|
| Rectum | 3 | 2018 | 61 | 0.210 |
Why?
|
| Neurilemmoma | 1 | 2002 | 16 | 0.210 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 346 | 0.210 |
Why?
|
| Time Factors | 3 | 2017 | 1640 | 0.200 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 2001 | 4 | 0.200 |
Why?
|
| Kidney Transplantation | 1 | 2003 | 126 | 0.190 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 52 | 0.190 |
Why?
|
| Treatment Failure | 2 | 2018 | 161 | 0.190 |
Why?
|
| Carcinosarcoma | 1 | 2000 | 4 | 0.180 |
Why?
|
| Kidney Pelvis | 1 | 2000 | 9 | 0.180 |
Why?
|
| Survival Rate | 2 | 2012 | 376 | 0.180 |
Why?
|
| Germinoma | 2 | 1996 | 2 | 0.180 |
Why?
|
| Ultrasonography, Interventional | 2 | 2018 | 63 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 78 | 0.160 |
Why?
|
| Urinary Incontinence, Stress | 1 | 1998 | 3 | 0.160 |
Why?
|
| Fluoroquinolones | 1 | 2018 | 25 | 0.160 |
Why?
|
| Surgical Procedures, Operative | 1 | 1998 | 30 | 0.160 |
Why?
|
| Osteomyelitis | 1 | 1998 | 23 | 0.160 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 42 | 0.160 |
Why?
|
| Ovariectomy | 1 | 2018 | 28 | 0.160 |
Why?
|
| Ureter | 1 | 2018 | 15 | 0.160 |
Why?
|
| Sickle Cell Trait | 1 | 1998 | 3 | 0.160 |
Why?
|
| Hysterectomy | 1 | 2018 | 20 | 0.160 |
Why?
|
| Preoperative Period | 1 | 2018 | 66 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 80 | 0.150 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 7 | 0.150 |
Why?
|
| Renal Veins | 1 | 2017 | 3 | 0.150 |
Why?
|
| Renal Artery | 1 | 2017 | 6 | 0.150 |
Why?
|
| Surgical Stapling | 1 | 2017 | 6 | 0.150 |
Why?
|
| Urinary Catheterization | 1 | 1997 | 6 | 0.140 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 37 | 0.140 |
Why?
|
| Laparoscopy | 2 | 2017 | 143 | 0.140 |
Why?
|
| Risk Factors | 3 | 2018 | 2466 | 0.140 |
Why?
|
| Amebiasis | 1 | 1996 | 3 | 0.140 |
Why?
|
| Fournier Gangrene | 1 | 1996 | 2 | 0.140 |
Why?
|
| Penile Diseases | 1 | 1996 | 8 | 0.140 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 1996 | 9 | 0.140 |
Why?
|
| Self Report | 1 | 2017 | 221 | 0.140 |
Why?
|
| Postoperative Care | 1 | 1997 | 127 | 0.140 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 98 | 0.130 |
Why?
|
| Genital Diseases, Male | 2 | 2011 | 5 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 1997 | 198 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 149 | 0.130 |
Why?
|
| Incidence | 4 | 2018 | 759 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2012 | 376 | 0.130 |
Why?
|
| Cryosurgery | 1 | 1995 | 20 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1997 | 329 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 401 | 0.130 |
Why?
|
| Penis | 1 | 1996 | 67 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 2 | 2005 | 16 | 0.120 |
Why?
|
| Prognosis | 3 | 2010 | 874 | 0.120 |
Why?
|
| Penile Induration | 1 | 1996 | 100 | 0.120 |
Why?
|
| Hernia, Inguinal | 1 | 2013 | 16 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 4941 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 636 | 0.110 |
Why?
|
| Melanoma | 1 | 2013 | 52 | 0.110 |
Why?
|
| Comorbidity | 3 | 2018 | 504 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 364 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2012 | 53 | 0.100 |
Why?
|
| Kidney | 1 | 2013 | 176 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 778 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2012 | 310 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2010 | 28 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2017 | 3557 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2010 | 18 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2011 | 117 | 0.090 |
Why?
|
| Young Adult | 2 | 2017 | 1966 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 177 | 0.090 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 30 | 0.090 |
Why?
|
| Piperazines | 1 | 2010 | 93 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 252 | 0.080 |
Why?
|
| Adolescent | 4 | 1997 | 2331 | 0.080 |
Why?
|
| Physical Examination | 2 | 2005 | 117 | 0.070 |
Why?
|
| Retroperitoneal Space | 2 | 1997 | 13 | 0.070 |
Why?
|
| Cystectomy | 1 | 2006 | 4 | 0.070 |
Why?
|
| Urination Disorders | 1 | 2005 | 7 | 0.060 |
Why?
|
| Auscultation | 1 | 2005 | 6 | 0.060 |
Why?
|
| Pleura | 1 | 2005 | 9 | 0.060 |
Why?
|
| Respiratory Sounds | 1 | 2005 | 10 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2005 | 28 | 0.060 |
Why?
|
| Case Management | 1 | 2005 | 13 | 0.060 |
Why?
|
| Catheterization, Central Venous | 1 | 2005 | 42 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2005 | 71 | 0.060 |
Why?
|
| Biopsy | 2 | 2018 | 239 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 32 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2004 | 23 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 558 | 0.060 |
Why?
|
| Injections | 1 | 2003 | 57 | 0.060 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 4 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 414 | 0.050 |
Why?
|
| Urinary Tract Infections | 1 | 2003 | 32 | 0.050 |
Why?
|
| Length of Stay | 1 | 2005 | 320 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2003 | 73 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 270 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 398 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 1186 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 1997 | 87 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 53 | 0.050 |
Why?
|
| Education | 1 | 2019 | 40 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2018 | 34 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 53 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2018 | 66 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 1997 | 36 | 0.040 |
Why?
|
| Lung | 1 | 2018 | 158 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2017 | 110 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2018 | 402 | 0.040 |
Why?
|
| Arteriovenous Fistula | 1 | 2017 | 10 | 0.040 |
Why?
|
| Ligation | 1 | 2017 | 31 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 286 | 0.040 |
Why?
|
| Urethra | 1 | 1997 | 15 | 0.040 |
Why?
|
| Ejaculation | 1 | 1996 | 8 | 0.040 |
Why?
|
| Fertility | 1 | 1996 | 19 | 0.040 |
Why?
|
| Spinal Nerve Roots | 1 | 1996 | 28 | 0.030 |
Why?
|
| Operative Time | 1 | 2017 | 81 | 0.030 |
Why?
|
| Mediastinal Neoplasms | 1 | 1996 | 13 | 0.030 |
Why?
|
| Impotence, Vasculogenic | 1 | 1996 | 4 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 334 | 0.030 |
Why?
|
| Patient Discharge | 1 | 1997 | 151 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 259 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 8 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 18 | 0.020 |
Why?
|
| Colectomy | 1 | 2010 | 20 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 683 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 63 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 532 | 0.010 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2003 | 19 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 852 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 1821 | 0.010 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2003 | 303 | 0.010 |
Why?
|